Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-024-02618-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Taigo Kato und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Oska, 565-0871, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Axitinib, Carcinoma, Renal Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck KGaA, Pfizer.
Abstract (Originalsprache)
Background
Avelumab + axitinib was approved for advanced renal cell carcinoma (aRCC) in Japan in December 2019. We report long-term real-world outcomes with first-line avelumab + axitinib from the J-DART2 study in Japan.
Methods
J-DART2 was a multicenter, noninterventional, retrospective study examining clinical data from patients with curatively unresectable locally advanced or metastatic RCC who started treatment with first-line avelumab + axitinib in Japan between December 2019 and October 2022. Endpoints included patient characteristics, treatment patterns, and outcomes.
Results
Data from 150 patients across 19 sites were analyzed; median follow-up was 18.7 months (95% CI, 16.3–20.6 months). Median age was 70.5 years; 26.0% of patients were aged ≤64 years, 42.7% were aged 65–74 years, and 31.3% were aged ≥75 years. International Metastatic RCC Database Consortium risk was favorable in 26.0%, intermediate in 54.7% (1 risk factor in 30.7%; 2 risk factors in 24.0%), and poor in 19.3% of patients. Median progression-free survival (PFS) was 17.1 months, with 1- and 2-year PFS rates of 57.7% and 37.5%, respectively. Median overall survival (OS) was not reached, with 1- and 2-year OS rates of 90.6% and 84.7%, respectively. Objective response rate was 53.3%; disease control rate was 88.9%. Outcomes were similar across age groups, including patients aged ≥75 years.
Conclusions
J-DART2 is the largest retrospective study to report long-term real-world outcomes in patients with aRCC treated with avelumab + axitinib in Japan. Findings were similar to those observed in previous studies and support the benefit of avelumab + axitinib in clinical practice in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Oska, 565-0871, Japan.
- Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
- Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima, 734-8551, Japan.
- Department of Urology, Kurume University School of Medicine, Asahi-Machi 67, Kurume-shi, Fukuoka, 830-0011, Japan.
- Department of Urology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
- Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Förderung
- Merck KGaA
- Pfizer
Zitieren
APA
Kato, T., Furukawa, J., Hinata, N., Ueda, K., Hara, I., Hongo, F., Mizuno, R., Okamoto, T., Okuno, H., Ito, T., Kajita, M., Oya, M., Tomita, Y., Shinohara, N., Eto, M., & Uemura, H. (2025). Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02618-9
Vancouver
Kato T, Furukawa J, Hinata N, Ueda K, Hara I, Hongo F, et al. Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02618-9
BibTeX
@article{Kato2025,
author = {Kato, Taigo and Furukawa, Junya and Hinata, Nobuyuki and Ueda, Kosuke and Hara, Isao and Hongo, Fumiya and Mizuno, Ryuichi and Okamoto, Teppei and Okuno, Hiroshi and Ito, Takayuki and Kajita, Masahiro and Oya, Mototsugu and Tomita, Yoshihiko and Shinohara, Nobuo and Eto, Masatoshi and Uemura, Hirotsugu},
title = {Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-024-02618-9}
}
EUVIMED